Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
MANTIS logo

MANTIS has been given the greenlight and is now open to recruitment.

 At present, there is little evidence for an effective drug in the treatment of Avascular Necrosis (AVN) of the femoral head. This is an uncommon yet devastating condition, primarily effecting a younger patient population. The MANTIS trial is a blinded, randomised, placebo controlled trial looking at the use of bisphosphonates and whether they can help to delay or prevent the progression of AVN.

 If you would like to be involved as a recruiting site, please contact mantis@ndorms.ox.ac.uk or follow the trial on twitter for the latest news @mantis_trial

Similar stories

SCIENCE spreads across the world

Oxford Trauma are pleased to open their first overseas site for the SCIENCE study.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

PRoCuRe opens to recruitment

The Partial Rotator Cuff Tear Repair Trial (PRoCuRe) is open to recruitment at Oxford University Hospitals NHS Foundation Trust after achieving OCTRU Green Light approval!

IMP-MEL Trial given Green Light to open

OCTRU have now given Green Light approval for IMP MEL to open. This is a phase 1 first-in-human dose finding/randomised phase 2 study of IMM60 and pembrolizumab in advanced melanoma and NSCLC.

WISE opens to recruitment

The WISE Study - Wrist Injury Strengthening Exercise: a randomised multicentre feasibility study of resistance exercise versus usual care for optimising function after distal radius fracture in adults aged 50 years or over has now received OCTRU Green Light approval and has opened to recruitment.